Bank of New York Mellon Corp Has $7.47 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Bank of New York Mellon Corp grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 11.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 396,399 shares of the company's stock after buying an additional 41,881 shares during the period. Bank of New York Mellon Corp owned approximately 0.86% of Pacira BioSciences worth $7,468,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PCRX. Pacer Advisors Inc. lifted its holdings in Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company's stock worth $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock valued at $5,955,000 after purchasing an additional 288,662 shares during the period. Janney Montgomery Scott LLC acquired a new stake in shares of Pacira BioSciences in the third quarter worth $793,000. Empowered Funds LLC bought a new stake in shares of Pacira BioSciences during the 3rd quarter worth $3,286,000. Finally, Verition Fund Management LLC bought a new stake in shares of Pacira BioSciences during the 3rd quarter worth $493,000. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock traded up $0.62 during mid-day trading on Wednesday, reaching $24.29. 303,396 shares of the stock were exchanged, compared to its average volume of 892,736. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -11.95 and a beta of 0.86. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a 50-day simple moving average of $24.15 and a 200 day simple moving average of $19.42.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have weighed in on PCRX. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC boosted their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. HC Wainwright raised their target price on Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a report on Friday, February 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays increased their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and a consensus price target of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.